Novo Nordisk A/S successfully opposed the trademark application for STOPOZEMPIC filed by Wallenberg Union LLC (Opposition No. 91298952, filed May 14, 2025). The TTAB sustained the opposition on April 4, 2026, blocking registration of the mark. Novo Nordisk established its prior rights in the OZEMPIC mark for pharmaceutical preparations.

The decision is binding on the named parties only and does not create industry-wide obligations. Trademark applicants should ensure their marks do not create confusion with established pharmaceutical brands, particularly for marks that incorporate well-known drug names with modifying prefixes or suffixes. No compliance actions are required by parties outside this proceeding.